{"protocolSection":{"identificationModule":{"nctId":"NCT02052739","orgStudyIdInfo":{"id":"547-SSE-201"},"organization":{"fullName":"Supernus Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus","officialTitle":"An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus","acronym":"SRSE"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-03-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2015-05-03","type":"ACTUAL"},"completionDateStruct":{"date":"2015-05-03","type":"ACTUAL"},"studyFirstSubmitDate":"2014-01-28","studyFirstSubmitQcDate":"2014-01-30","studyFirstPostDateStruct":{"date":"2014-02-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-02-16","resultsFirstSubmitQcDate":"2022-04-05","resultsFirstPostDateStruct":{"date":"2022-05-03","type":"ACTUAL"},"dispFirstSubmitDate":"2017-04-25","dispFirstSubmitQcDate":"2017-04-25","dispFirstPostDateStruct":{"date":"2017-04-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-11","lastUpdatePostDateStruct":{"date":"2025-09-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Supernus Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).","detailedDescription":"This is an open-label study consisting of a screening period (1 day), 4-day treatment period (96 hours) followed by a 1-day dose taper period (24 hours), a 2-day acute follow-up period, and a 3 week extended follow-up period.\n\nOn Day 1 of treatment SRSE participants under seizure suppression or burst-suppression with a continuous intravenous (IV) anti-epileptic drug (AED) (third-line agent) were given a 1-hour IV loading infusion of SAGE-547 followed by a maintenance infusion. After 48 hours of SAGE-547 treatment, the continuous IV AED (third-line agent) was weaned while continuing SAGE-547 at the maintenance infusion for the remainder of the treatment period. After 96 hours (4 days) of therapy with SAGE-547, the dose was to be tapered and discontinued over 24 hours.\n\nThe participants would have routine continuous electroencephalogram (EEG) monitoring during the screening period, and continuing until 48 hours after SAGE-547 treatment had completed. Participants would then have follow-up examinations weekly for the next 3 weeks (Days 8, 15, 22, and 29), during which safety and functional assessments would be obtained. Apart from treatment with SAGE-547, all participants would receive the standard of care for adults in SRSE along with ongoing treatment for all underlying medical conditions."},"conditionsModule":{"conditions":["Super-refractory Status Epilepticus"],"keywords":["Status Epilepticus","Refractory status epilepticus","Super-refractory status epilepticus","SAGE-547","SAGE","Sage Therapeutics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":25,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"SAGE-547 Standard Dose","type":"EXPERIMENTAL","description":"Participants received SAGE-547 IV loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.","interventionNames":["Drug: SAGE-547"]},{"label":"SAGE-547 High Dose","type":"EXPERIMENTAL","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.","interventionNames":["Drug: SAGE-547"]}],"interventions":[{"type":"DRUG","name":"SAGE-547","description":"Solution for injection for IV infusion","armGroupLabels":["SAGE-547 High Dose","SAGE-547 Standard Dose"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.","timeFrame":"Up to Day 29"},{"measure":"Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score","description":"The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Body Weight","description":"Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Heart Rate","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended Follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72: 72 hour;73-96: 96 hour;97-120:120 hour;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8,15,22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Respiratory Rate","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Body Temperature","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Vital Sign Parameter: Oxygen Saturation","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Albumin Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Bicarbonate Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Bilirubin Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Calcium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Chloride Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Creatinine Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Glucose Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Lipase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Magnesium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Potassium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Protein Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Serum Chemistry Parameter: Sodium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Basophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Eosinophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Erythrocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Hematocrit Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Hemoglobin Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Leukocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Lymphocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Monocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Neutrophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Hematology Parameter: Platelet Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate","description":"ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval","description":"ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage","description":"Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.","timeFrame":"Up to Day 29"}],"secondaryOutcomes":[{"measure":"Number of Participants With Relapse - Re-Initiation of Third-Line Agent","description":"Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.","timeFrame":"Up to Day 29"},{"measure":"Number of Participants With Treatment Response (Treatment Responders)","description":"A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).","timeFrame":"Up to 96 hours"},{"measure":"Duration of Response","description":"Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.","timeFrame":"Up to Day 29"},{"measure":"Maximum Plasma Concentration (Cmax) of SAGE-547","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose"},{"measure":"Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose"},{"measure":"Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose"},{"measure":"Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8 and 24 hours post-dose"},{"measure":"Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose"},{"measure":"Average Plasma Concentration (Cav) of SAGE-547","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose"},{"measure":"Plasma Clearance (CL) of SAGE-547","description":"Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose"},{"measure":"Change From Baseline in Modified Rankin Scale (mRS-9Q) Scores","description":"The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.","timeFrame":"Baseline (Screening) to Infusion at 49-72 hour, 73-96 hour; Extended follow-up at Day 8, 15, 22 and 29"},{"measure":"Change From Baseline in Clinical Global Impression: Severity Scale (CGI-S)","description":"The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question \"Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?\" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.","timeFrame":"Baseline (Screening), Extended follow-up at Days 8, 15, 22, and 29"},{"measure":"Clinical Global Impression: Improvement Scale (CGI-I) Scores","description":"The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.","timeFrame":"Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Glasgow Coma Scale (GCS) Scores","description":"The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Change From Baseline in Richmond Agitation Sedation Scale (RASS) Score","description":"The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.","timeFrame":"Baseline (Screening) to Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29"},{"measure":"Number of Participants Who Survived","description":"Survival time was defined as duration of survival from screening up to Day 29.","timeFrame":"Up to Day 29"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants 2 years of age and older.\n* Participants with an EEG-confirmed SRSE diagnosis under concomitant therapy with a continuous IV AED (third-line agent) for ≥ 24 hours. For this study, SRSE is defined by the following criteria and in accordance with those used at major epilepsy treatment centers:\n\n  * Failure to respond to the administration of at least one first-line agent (e.g., benzodiazepine or other emergent initial AED treatment), according to institution standard of care, and\n  * Failure to respond to at least one second-line agent (e.g., phenytoin, fosphenytoin, valproate, phenobarbital, levetiracetam or other urgent control AED) according to institution standard of care, and\n  * Presence of one or more breakthrough seizures \\> 6 hours after initiation of the continuous IV AED/third-line agent (e.g., pentobarbital, midazolam, propofol).\n\nExclusion Criteria:\n\n* Participants with SRSE due to anoxic/hypoxic encephalopathy, children (participants aged less than 18 years) with an encephalopathy due to an underlying progressive neurological disorder.\n* Participants with clinically significant electrocardiogram abnormalities.\n* Participants with a significant medical or surgical condition that may compromise vital organ systems, or other conditions that would place the participants at increased risk such as dialysis or acute respiratory distress syndrome, severe cardiogenic or vasodilatory shock requiring 2 or more pressors, fulminant hepatic failure, etc.\n* Participants who are receiving a continuous IV AED (third-line agent) for seizure suppression or burst-suppression that would require greater than 24 hours to wean.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Robert Lasser, MD, MBA","affiliation":"Sage Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Sage Investigational Site","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Sage Investigational Site","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Sage Investigational Site","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Sage Investigational Site","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Sage Investigational Site","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Sage Investigational Site","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Sage Investigational Site","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Sage Investigational Site","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Sage Investigational Site","city":"Detroit","state":"Michigan","zip":"48322","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Sage Investigational Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Sage Investigational Site","city":"Rochester","state":"New York","zip":"14642","country":"United States","geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"Sage Investigational Site","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Sage Investigational Site","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Sage Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Sage Investigational Site","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Sage Investigational Site","city":"Dallas","state":"Texas","zip":"75251","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Sage Investigational Site","city":"Temple","state":"Texas","zip":"76504","country":"United States","geoPoint":{"lat":31.09823,"lon":-97.34278}}]},"referencesModule":{"references":[{"pmid":"28779545","type":"BACKGROUND","citation":"Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, Hoffmann E, Colquhoun H, Doherty JJ, Kanes SJ. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017 Sep;82(3):342-352. doi: 10.1002/ana.25008. Epub 2017 Sep 11."}],"seeAlsoLinks":[{"label":"Sage Therapeutics","url":"http://www.sagerx.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Data sharing will be consistent with the results submission policy of ClinicalTrials.gov."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 25 participants were enrolled into the study to receive either SAGE-547 standard dose or SAGE-547 high dose,19 participants of whom completed the study.","recruitmentDetails":"Participants took part in the study at 12 sites in United States from 21 March 2014 to 03 May 2015.","groups":[{"id":"FG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 intravenous (IV) loading infusion of 286.6 micrograms per kilogram per hour (μg/kg/hr) for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"FG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Withdrew due to Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Participant Died","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547.","groups":[{"id":"BG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"BG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"25"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49.3","spread":"18.98"},{"groupId":"BG001","value":"42.3","spread":"22.11"},{"groupId":"BG002","value":"47.6","spread":"19.52"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"16"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"23"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"19"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAEs are defined as those that begin on or after initiation of the infusion of SAGE-547.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline (CFB) in National Institutes of Health Stroke Scale (NIH-SS) Total Score","description":"The National Institutes of Health Stroke Scale (NIH-SS) was used to examine the physical and neurological state of the participants. The NIH-SS is a 15-item assessment with measures of level of consciousness, visual gaze and vision loss, facial palsy, motor ability, ataxia, sensory ability, aphasia, dysarthria, and inattention. The total NIHSS score range is from 0 (normal) to 42 (severe impairment), with higher values indicating greater level of neurological impairment.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":"4.69"},{"groupId":"OG001","value":"33.0","spread":"4.86"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.30"},{"groupId":"OG001","value":"0.3","spread":"1.51"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"3.47"},{"groupId":"OG001","value":"-1.5","spread":"6.19"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"6.70"},{"groupId":"OG001","value":"-2.3","spread":"4.63"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"8.08"},{"groupId":"OG001","value":"-5.5","spread":"6.63"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"7.44"},{"groupId":"OG001","value":"-6.7","spread":"7.20"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"8.75"},{"groupId":"OG001","value":"-10.8","spread":"10.13"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"9.78"},{"groupId":"OG001","value":"-12.0","spread":"8.76"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"9.54"},{"groupId":"OG001","value":"-15.4","spread":"11.82"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":"12.10"},{"groupId":"OG001","value":"-16.6","spread":"13.30"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.1","spread":"14.35"},{"groupId":"OG001","value":"-17.2","spread":"14.55"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","spread":"15.34"},{"groupId":"OG001","value":"-20.6","spread":"13.09"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Body Weight","description":"Vital signs included weight, heart rate, blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)), respiratory rate, temperature, oxygen saturation. CFB in body weight is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms (kg)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.263","spread":"25.3905"},{"groupId":"OG001","value":"81.667","spread":"20.3141"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.253","spread":"3.3321"},{"groupId":"OG001","value":"0.250","spread":"0.3987"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.095","spread":"3.9392"},{"groupId":"OG001","value":"1.083","spread":"2.1424"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.444","spread":"3.5787"},{"groupId":"OG001","value":"-0.933","spread":"2.9561"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.517","spread":"4.5509"},{"groupId":"OG001","value":"-0.033","spread":"4.4275"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.688","spread":"4.3148"},{"groupId":"OG001","value":"1.567","spread":"8.8672"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.631","spread":"6.3734"},{"groupId":"OG001","value":"1.650","spread":"12.6751"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.930","spread":"7.7080"},{"groupId":"OG001","value":"-5.100","spread":"4.8298"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.436","spread":"9.5258"},{"groupId":"OG001","value":"-1.720","spread":"7.6392"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.708","spread":"10.1362"},{"groupId":"OG001","value":"-6.100","spread":"4.7589"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.644","spread":"8.9288"},{"groupId":"OG001","value":"-3.420","spread":"12.4474"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.130","spread":"13.5243"},{"groupId":"OG001","value":"0.108","spread":"19.4907"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Heart Rate","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in heart rate is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats per minute (beats/min)","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended Follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":"14.33"},{"groupId":"OG001","value":"81.8","spread":"20.90"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.65"},{"groupId":"OG001","value":"-0.5","spread":"2.12"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"3.36"},{"groupId":"OG001","value":"0.6","spread":"1.52"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"5.26"},{"groupId":"OG001","value":"-2.0","spread":"2.45"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"3.98"},{"groupId":"OG001","value":"-3.6","spread":"4.10"}]}]},{"title":"CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"4.18"},{"groupId":"OG001","value":"-4.7","spread":"7.26"}]}]},{"title":"CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"4.92"},{"groupId":"OG001","value":"-0.5","spread":"7.56"}]}]},{"title":"CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"7.65"},{"groupId":"OG001","value":"-2.8","spread":"8.52"}]}]},{"title":"CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"9.87"},{"groupId":"OG001","value":"-10.7","spread":"10.07"}]}]},{"title":"CFB at Infusion: 0-24 hours: 24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"13.52"},{"groupId":"OG001","value":"1.8","spread":"7.11"}]}]},{"title":"CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"15.09"},{"groupId":"OG001","value":"-4.8","spread":"8.04"}]}]},{"title":"CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"13.65"},{"groupId":"OG001","value":"2.7","spread":"12.42"}]}]},{"title":"CFB at Infusion: 73-96 hours: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"14.03"},{"groupId":"OG001","value":"8.0","spread":"14.38"}]}]},{"title":"CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"13.43"},{"groupId":"OG001","value":"10.7","spread":"28.86"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"13.10"},{"groupId":"OG001","value":"18.0","spread":"23.33"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"15.77"},{"groupId":"OG001","value":"14.8","spread":"17.17"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"12.69"},{"groupId":"OG001","value":"5.6","spread":"15.34"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"15.66"},{"groupId":"OG001","value":"6.0","spread":"12.63"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"11.92"},{"groupId":"OG001","value":"13.6","spread":"27.88"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":"16.19"},{"groupId":"OG001","value":"11.2","spread":"26.54"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Blood Pressure - SBP and DBP","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in SBP and DBP is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimeters of mercury (mmHg)","timeFrame":"Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72: 72 hour;73-96: 96 hour;97-120:120 hour;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8,15,22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"SBP Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"111.1","spread":"14.55"},{"groupId":"OG001","value":"111.8","spread":"7.46"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"13.23"},{"groupId":"OG001","value":"20.0","spread":"28.28"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"8.36"},{"groupId":"OG001","value":"5.0","spread":"11.85"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"12.64"},{"groupId":"OG001","value":"3.8","spread":"11.12"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"12.55"},{"groupId":"OG001","value":"-9.4","spread":"12.22"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"11.96"},{"groupId":"OG001","value":"-6.8","spread":"11.39"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"15.96"},{"groupId":"OG001","value":"-5.7","spread":"19.72"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"14.40"},{"groupId":"OG001","value":"-1.7","spread":"11.81"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"18.55"},{"groupId":"OG001","value":"-1.3","spread":"18.02"}]}]},{"title":"SBP CFB at Infusion: 0-24 hours: 24 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"19.26"},{"groupId":"OG001","value":"5.7","spread":"17.63"}]}]},{"title":"SBP CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"21.49"},{"groupId":"OG001","value":"2.5","spread":"21.55"}]}]},{"title":"SBP CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"27.72"},{"groupId":"OG001","value":"3.0","spread":"23.83"}]}]},{"title":"SBP CFB at Infusion: 73-96 hours: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"24.06"},{"groupId":"OG001","value":"11.8","spread":"24.39"}]}]},{"title":"SBP CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"22.13"},{"groupId":"OG001","value":"-1.8","spread":"21.04"}]}]},{"title":"SBP CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"18.67"},{"groupId":"OG001","value":"12.8","spread":"21.58"}]}]},{"title":"SBP CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"24.46"},{"groupId":"OG001","value":"7.0","spread":"25.93"}]}]},{"title":"SBP CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"21.12"},{"groupId":"OG001","value":"5.0","spread":"16.02"}]}]},{"title":"SBP CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"19.55"},{"groupId":"OG001","value":"3.2","spread":"11.52"}]}]},{"title":"SBP CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"27.60"},{"groupId":"OG001","value":"7.0","spread":"6.75"}]}]},{"title":"SBP CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"24.20"},{"groupId":"OG001","value":"2.8","spread":"19.77"}]}]},{"title":"DBP Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":"8.51"},{"groupId":"OG001","value":"60.8","spread":"10.69"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"10.53"},{"groupId":"OG001","value":"7.5","spread":"10.61"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"5.83"},{"groupId":"OG001","value":"2.2","spread":"4.15"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"10.38"},{"groupId":"OG001","value":"3.6","spread":"5.41"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"6.26"},{"groupId":"OG001","value":"-3.6","spread":"7.33"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"8.17"},{"groupId":"OG001","value":"-1.8","spread":"3.25"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"6.70"},{"groupId":"OG001","value":"-3.2","spread":"9.56"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"7.36"},{"groupId":"OG001","value":"0.0","spread":"8.67"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"7.11"},{"groupId":"OG001","value":"-5.0","spread":"12.17"}]}]},{"title":"DBP CFB at Infusion: 0-24 hours: 24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"12.61"},{"groupId":"OG001","value":"6.3","spread":"24.99"}]}]},{"title":"DBP CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"9.01"},{"groupId":"OG001","value":"-4.0","spread":"7.87"}]}]},{"title":"DBP CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"16.37"},{"groupId":"OG001","value":"-4.2","spread":"5.42"}]}]},{"title":"DBP CFB at Infusion: 73-96 hours: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"12.09"},{"groupId":"OG001","value":"3.3","spread":"7.58"}]}]},{"title":"DBP CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"12.65"},{"groupId":"OG001","value":"1.0","spread":"12.13"}]}]},{"title":"DBP CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"11.53"},{"groupId":"OG001","value":"6.6","spread":"8.99"}]}]},{"title":"DBP CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"18.15"},{"groupId":"OG001","value":"3.0","spread":"18.59"}]}]},{"title":"DBP CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"12.40"},{"groupId":"OG001","value":"1.0","spread":"10.89"}]}]},{"title":"DBP CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"11.13"},{"groupId":"OG001","value":"4.8","spread":"6.22"}]}]},{"title":"DBP CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"14.67"},{"groupId":"OG001","value":"13.4","spread":"11.72"}]}]},{"title":"DBP CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"11.02"},{"groupId":"OG001","value":"12.4","spread":"22.78"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Respiratory Rate","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in respiratory rate is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"breaths per min (breaths/min)","timeFrame":"Baseline (Screening) to infusion at 0-24 hours:Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours;Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"4.66"},{"groupId":"OG001","value":"13.4","spread":"3.58"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.75"},{"groupId":"OG001","value":"-2.0","spread":"1.41"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.39"},{"groupId":"OG001","value":"-0.6","spread":"0.89"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"3.05"},{"groupId":"OG001","value":"-1.0","spread":"1.41"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.64"},{"groupId":"OG001","value":"1.0","spread":"2.65"}]}]},{"title":"CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.24"},{"groupId":"OG001","value":"0.2","spread":"1.47"}]}]},{"title":"CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.78"},{"groupId":"OG001","value":"0.8","spread":"1.33"}]}]},{"title":"CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.98"},{"groupId":"OG001","value":"-0.2","spread":"1.33"}]}]},{"title":"CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.14"},{"groupId":"OG001","value":"-0.3","spread":"1.86"}]}]},{"title":"CFB at Infusion: 0-24 hours: 24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"4.08"},{"groupId":"OG001","value":"0.7","spread":"1.51"}]}]},{"title":"CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.21"},{"groupId":"OG001","value":"-0.8","spread":"3.66"}]}]},{"title":"CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"3.65"},{"groupId":"OG001","value":"1.0","spread":"6.96"}]}]},{"title":"CFB at Infusion: 73-96 hours: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"6.87"},{"groupId":"OG001","value":"1.2","spread":"6.97"}]}]},{"title":"CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"5.62"},{"groupId":"OG001","value":"1.0","spread":"4.90"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"4.25"},{"groupId":"OG001","value":"1.4","spread":"5.77"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"6.08"},{"groupId":"OG001","value":"6.0","spread":"6.32"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"5.94"},{"groupId":"OG001","value":"0.6","spread":"3.05"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"5.87"},{"groupId":"OG001","value":"5.0","spread":"6.40"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"4.32"},{"groupId":"OG001","value":"3.0","spread":"6.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"6.35"},{"groupId":"OG001","value":"5.6","spread":"11.28"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Body Temperature","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. CFB in body temperature is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"degrees Fahrenheit (F)","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.21","spread":"1.195"},{"groupId":"OG001","value":"98.98","spread":"2.312"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"0.883"},{"groupId":"OG001","value":"-0.30","spread":"0.707"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"0.471"},{"groupId":"OG001","value":"-0.04","spread":"0.329"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.628"},{"groupId":"OG001","value":"-0.14","spread":"0.371"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":"0.662"},{"groupId":"OG001","value":"-0.32","spread":"0.432"}]}]},{"title":"CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.614"},{"groupId":"OG001","value":"-0.55","spread":"0.468"}]}]},{"title":"CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.902"},{"groupId":"OG001","value":"-0.48","spread":"0.407"}]}]},{"title":"CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.269"},{"groupId":"OG001","value":"-0.47","spread":"0.596"}]}]},{"title":"CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"1.361"},{"groupId":"OG001","value":"-0.52","spread":"0.985"}]}]},{"title":"CFB at Infusion: 0-24 hours: 24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.704"},{"groupId":"OG001","value":"0.20","spread":"1.474"}]}]},{"title":"CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"1.467"},{"groupId":"OG001","value":"-0.47","spread":"1.335"}]}]},{"title":"CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"1.522"},{"groupId":"OG001","value":"-0.47","spread":"1.296"}]}]},{"title":"CFB at Infusion: 73-96 hour: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"1.263"},{"groupId":"OG001","value":"-0.62","spread":"1.283"}]}]},{"title":"CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"1.230"},{"groupId":"OG001","value":"-0.92","spread":"1.514"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"1.360"},{"groupId":"OG001","value":"-0.16","spread":"1.450"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"1.896"},{"groupId":"OG001","value":"-0.20","spread":"0.652"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.010"},{"groupId":"OG001","value":"-0.46","spread":"0.684"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"1.852"},{"groupId":"OG001","value":"-0.42","spread":"0.740"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"1.834"},{"groupId":"OG001","value":"-0.96","spread":"1.790"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"1.515"},{"groupId":"OG001","value":"-1.20","spread":"2.164"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Vital Sign Parameter: Oxygen Saturation","description":"Vital signs included weight, heart rate, blood pressure (SBP and DBP), respiratory rate, temperature, oxygen saturation. Oxygen saturation is a measure of how much hemoglobin is currently bound to oxygen compared to how much hemoglobin remains unbound. CFB in oxygen saturation is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of oxygen saturation","timeFrame":"Baseline (Screening) to infusion at 0-24 hours: Loading-predose and at 15,30,45 minutes;1,2,4,8 and 24 hour;25-48: 48 hour;49-72:72 hours;73-96: 96 hour;97-120:120 hours;Acute follow-up at 121-144,145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.8","spread":"2.26"},{"groupId":"OG001","value":"98.6","spread":"1.67"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - Pre-Dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"},{"groupId":"OG001","value":"0.5","spread":"0.71"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 15 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.33"},{"groupId":"OG001","value":"0.2","spread":"0.45"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 30 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.45"},{"groupId":"OG001","value":"0.4","spread":"1.52"}]}]},{"title":"CFB at Infusion: 0-24 hours: Loading - 45 minutes","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.08"},{"groupId":"OG001","value":"0.2","spread":"1.92"}]}]},{"title":"CFB at Infusion: 0-24 hours: 1 hour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.48"},{"groupId":"OG001","value":"0.0","spread":"1.55"}]}]},{"title":"CFB at Infusion: 0-24 hours: 2 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.10"},{"groupId":"OG001","value":"-1.3","spread":"4.76"}]}]},{"title":"CFB at Infusion: 0-24 hours: 4 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.69"},{"groupId":"OG001","value":"1.2","spread":"1.33"}]}]},{"title":"CFB at Infusion: 0-24 hours: 8 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.45"},{"groupId":"OG001","value":"1.0","spread":"0.89"}]}]},{"title":"CFB at Infusion: 0-24 hours: 24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.15"},{"groupId":"OG001","value":"-0.7","spread":"1.75"}]}]},{"title":"CFB at Infusion: 25-48 hours: 48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.75"},{"groupId":"OG001","value":"0.8","spread":"0.98"}]}]},{"title":"CFB at Infusion: 49-72 hours: 72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.01"},{"groupId":"OG001","value":"0.3","spread":"1.97"}]}]},{"title":"CFB at Infusion: 73-96 hours: 96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.95"},{"groupId":"OG001","value":"-0.8","spread":"2.48"}]}]},{"title":"CFB at Infusion: 97-120 hours: 120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.62"},{"groupId":"OG001","value":"-1.3","spread":"2.34"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.11"},{"groupId":"OG001","value":"0.0","spread":"1.58"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.31"},{"groupId":"OG001","value":"-0.8","spread":"2.86"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.58"},{"groupId":"OG001","value":"-0.2","spread":"1.64"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.90"},{"groupId":"OG001","value":"0.4","spread":"0.55"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"22.32"},{"groupId":"OG001","value":"0.6","spread":"1.52"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.54"},{"groupId":"OG001","value":"-1.2","spread":"1.30"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in alanine aminotransferase levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"international units per liter (IU/L)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":"82.92"},{"groupId":"OG001","value":"40.0","spread":"32.47"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"23.96"},{"groupId":"OG001","value":"17.0","spread":"42.85"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"39.62"},{"groupId":"OG001","value":"39.3","spread":"69.34"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"42.77"},{"groupId":"OG001","value":"36.5","spread":"48.02"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"50.97"},{"groupId":"OG001","value":"84.0","spread":"124.28"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"64.93"},{"groupId":"OG001","value":"233.3","spread":"475.33"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"75.63"},{"groupId":"OG001","value":"109.5","spread":"222.80"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"72.25"},{"groupId":"OG001","value":"48.5","spread":"107.03"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"69.89"},{"groupId":"OG001","value":"0.4","spread":"29.80"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"85.06"},{"groupId":"OG001","value":"32.2","spread":"47.21"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"46.91"},{"groupId":"OG001","value":"44.0","spread":"65.01"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":"309.38"},{"groupId":"OG001","value":"374.0","spread":"404.96"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Albumin Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in albumin levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"grams per liter (g/L)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":"4.87"},{"groupId":"OG001","value":"21.3","spread":"3.67"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.75"},{"groupId":"OG001","value":"-1.3","spread":"3.33"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.84"},{"groupId":"OG001","value":"-0.7","spread":"7.17"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.32"},{"groupId":"OG001","value":"0.7","spread":"5.28"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.26"},{"groupId":"OG001","value":"3.8","spread":"8.54"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"2.45"},{"groupId":"OG001","value":"5.0","spread":"6.60"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.82"},{"groupId":"OG001","value":"5.3","spread":"8.71"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"3.61"},{"groupId":"OG001","value":"7.5","spread":"8.96"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"4.34"},{"groupId":"OG001","value":"9.2","spread":"9.44"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"6.45"},{"groupId":"OG001","value":"10.2","spread":"6.22"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"7.46"},{"groupId":"OG001","value":"9.5","spread":"1.73"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"7.91"},{"groupId":"OG001","value":"12.3","spread":"4.04"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in aspartate aminotransferase levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":"50.41"},{"groupId":"OG001","value":"44.8","spread":"35.87"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"43.24"},{"groupId":"OG001","value":"18.3","spread":"31.42"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":"43.28"},{"groupId":"OG001","value":"32.7","spread":"30.66"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"40.40"},{"groupId":"OG001","value":"24.5","spread":"24.99"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"39.23"},{"groupId":"OG001","value":"146.7","spread":"328.43"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"39.62"},{"groupId":"OG001","value":"854.5","spread":"2056.68"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"35.16"},{"groupId":"OG001","value":"440.3","spread":"1067.48"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"29.27"},{"groupId":"OG001","value":"264.7","spread":"654.96"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"34.72"},{"groupId":"OG001","value":"-5.2","spread":"16.63"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"33.33"},{"groupId":"OG001","value":"29.0","spread":"48.93"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"68.73"},{"groupId":"OG001","value":"25.0","spread":"55.47"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"121.92"},{"groupId":"OG001","value":"1888.0","spread":"3115.96"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Bicarbonate Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bicarbonate levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per liter (mmol/L)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.29","spread":"5.247"},{"groupId":"OG001","value":"24.52","spread":"4.481"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"2.077"},{"groupId":"OG001","value":"-0.85","spread":"2.411"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"3.607"},{"groupId":"OG001","value":"-0.90","spread":"2.205"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"3.252"},{"groupId":"OG001","value":"-0.98","spread":"3.060"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"3.258"},{"groupId":"OG001","value":"-0.20","spread":"3.200"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"4.187"},{"groupId":"OG001","value":"-0.83","spread":"4.262"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"4.834"},{"groupId":"OG001","value":"-1.75","spread":"5.511"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"5.119"},{"groupId":"OG001","value":"-2.15","spread":"5.829"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","spread":"5.397"},{"groupId":"OG001","value":"-0.06","spread":"4.463"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"5.309"},{"groupId":"OG001","value":"1.14","spread":"6.527"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"6.239"},{"groupId":"OG001","value":"1.56","spread":"5.447"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"6.432"},{"groupId":"OG001","value":"0.25","spread":"6.850"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Bilirubin Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in bilirubin levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micromoles per liter (μmol/L)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3900","spread":"37.32086"},{"groupId":"OG001","value":"6.8400","spread":"7.41438"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8165","spread":"7.32863"},{"groupId":"OG001","value":"0.8550","spread":"2.35707"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0176","spread":"8.68845"},{"groupId":"OG001","value":"0.0000","spread":"5.72275"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0688","spread":"3.11420"},{"groupId":"OG001","value":"-1.4250","spread":"6.15758"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9237","spread":"5.14423"},{"groupId":"OG001","value":"-0.8550","spread":"5.59356"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3680","spread":"6.27296"},{"groupId":"OG001","value":"0.0000","spread":"7.33508"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4657","spread":"6.56677"},{"groupId":"OG001","value":"0.5700","spread":"9.34522"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9086","spread":"10.20347"},{"groupId":"OG001","value":"3.7050","spread":"14.56682"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2064","spread":"18.06184"},{"groupId":"OG001","value":"-2.0520","spread":"7.49284"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6292","spread":"25.00165"},{"groupId":"OG001","value":"-2.3940","spread":"7.31512"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.4197","spread":"18.18369"},{"groupId":"OG001","value":"-0.4275","spread":"5.10619"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.5050","spread":"69.14760"},{"groupId":"OG001","value":"2.2800","spread":"1.97454"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Blood Urea Nitrogen Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in blood urea nitrogen levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.7162","spread":"2.04935"},{"groupId":"OG001","value":"4.9980","spread":"1.62817"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5752","spread":"0.90926"},{"groupId":"OG001","value":"-0.1785","spread":"0.58661"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2025","spread":"1.55708"},{"groupId":"OG001","value":"-0.7140","spread":"1.17322"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3090","spread":"1.79547"},{"groupId":"OG001","value":"-0.8925","spread":"1.16778"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6462","spread":"2.02001"},{"groupId":"OG001","value":"-0.1785","spread":"1.99090"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0160","spread":"2.22925"},{"groupId":"OG001","value":"0.6545","spread":"2.82384"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1000","spread":"2.37104"},{"groupId":"OG001","value":"2.0825","spread":"2.79663"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1197","spread":"2.64106"},{"groupId":"OG001","value":"1.9040","spread":"2.79890"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8743","spread":"2.74527"},{"groupId":"OG001","value":"1.1424","spread":"2.55448"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5396","spread":"2.64507"},{"groupId":"OG001","value":"0.0714","spread":"2.14794"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0145","spread":"5.10015"},{"groupId":"OG001","value":"-0.0714","spread":"3.73914"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0115","spread":"3.40329"},{"groupId":"OG001","value":"1.3388","spread":"0.79160"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Calcium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in calcium levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2037","spread":"0.01153"},{"groupId":"OG001","value":"0.1950","spread":"0.02074"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0015","spread":"0.00733"},{"groupId":"OG001","value":"0.0021","spread":"0.00732"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0036","spread":"0.00984"},{"groupId":"OG001","value":"0.0017","spread":"0.01765"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0056","spread":"0.01521"},{"groupId":"OG001","value":"0.0067","spread":"0.02149"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0078","spread":"0.01522"},{"groupId":"OG001","value":"0.0079","spread":"0.02947"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0084","spread":"0.01714"},{"groupId":"OG001","value":"0.0117","spread":"0.02493"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0071","spread":"0.01703"},{"groupId":"OG001","value":"0.0125","spread":"0.02766"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0100","spread":"0.01180"},{"groupId":"OG001","value":"0.0092","spread":"0.02553"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0114","spread":"0.01016"},{"groupId":"OG001","value":"0.0170","spread":"0.01866"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0172","spread":"0.01873"},{"groupId":"OG001","value":"0.0170","spread":"0.01681"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0202","spread":"0.03017"},{"groupId":"OG001","value":"0.0219","spread":"0.00688"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0121","spread":"0.02749"},{"groupId":"OG001","value":"0.0300","spread":"0.00750"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Chloride Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in chloride levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.0","spread":"6.21"},{"groupId":"OG001","value":"109.7","spread":"3.72"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.82"},{"groupId":"OG001","value":"-3.5","spread":"3.56"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"3.32"},{"groupId":"OG001","value":"-0.5","spread":"5.17"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"3.74"},{"groupId":"OG001","value":"0.5","spread":"6.60"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"4.22"},{"groupId":"OG001","value":"-0.3","spread":"4.63"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"5.07"},{"groupId":"OG001","value":"-2.7","spread":"2.73"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"6.96"},{"groupId":"OG001","value":"-1.8","spread":"4.92"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"7.36"},{"groupId":"OG001","value":"-1.2","spread":"3.97"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"7.32"},{"groupId":"OG001","value":"-3.4","spread":"5.55"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"9.02"},{"groupId":"OG001","value":"-4.6","spread":"12.12"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"8.63"},{"groupId":"OG001","value":"-10.8","spread":"5.81"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"6.73"},{"groupId":"OG001","value":"-11.0","spread":"4.69"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Creatine Kinase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatine kinase levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"164.6","spread":"297.58"},{"groupId":"OG001","value":"1056.4","spread":"1476.88"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"99.29"},{"groupId":"OG001","value":"80.0","spread":"343.91"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-41.5","spread":"204.71"},{"groupId":"OG001","value":"-77.0","spread":"226.45"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-52.8","spread":"240.39"},{"groupId":"OG001","value":"-35.2","spread":"375.74"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-54.8","spread":"250.36"},{"groupId":"OG001","value":"187.8","spread":"428.72"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-69.4","spread":"267.62"},{"groupId":"OG001","value":"1034.6","spread":"2557.56"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-94.9","spread":"280.01"},{"groupId":"OG001","value":"864.2","spread":"2487.87"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-43.8","spread":"269.89"},{"groupId":"OG001","value":"1462.6","spread":"3745.02"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-39.5","spread":"286.63"},{"groupId":"OG001","value":"-67.0","spread":"684.14"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-70.5","spread":"293.08"},{"groupId":"OG001","value":"-294.5","spread":"520.14"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-108.7","spread":"284.99"},{"groupId":"OG001","value":"-245.5","spread":"217.08"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"51.57"},{"groupId":"OG001","value":"-356.7","spread":"596.58"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Creatinine Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in creatinine levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"μmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.8335","spread":"38.35138"},{"groupId":"OG001","value":"66.1527","spread":"26.85624"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5851","spread":"21.18016"},{"groupId":"OG001","value":"-4.2727","spread":"3.96981"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3257","spread":"17.04796"},{"groupId":"OG001","value":"-2.7993","spread":"9.97654"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4513","spread":"17.92081"},{"groupId":"OG001","value":"-5.1567","spread":"13.15250"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0364","spread":"24.69353"},{"groupId":"OG001","value":"2.6520","spread":"34.21891"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.1800","spread":"28.19797"},{"groupId":"OG001","value":"15.1753","spread":"34.57069"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4000","spread":"30.51166"},{"groupId":"OG001","value":"32.4133","spread":"73.92834"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5748","spread":"39.93224"},{"groupId":"OG001","value":"37.8647","spread":"103.07822"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8345","spread":"34.60628"},{"groupId":"OG001","value":"-1.5912","spread":"12.81648"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1825","spread":"30.96420"},{"groupId":"OG001","value":"-3.3592","spread":"13.75749"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6726","spread":"33.58740"},{"groupId":"OG001","value":"-11.6688","spread":"33.48365"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.7867","spread":"78.66321"},{"groupId":"OG001","value":"0.0000","spread":"23.06320"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Glucose Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in glucose levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0731","spread":"1.60940"},{"groupId":"OG001","value":"7.1238","spread":"2.48860"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7247","spread":"1.21847"},{"groupId":"OG001","value":"2.5905","spread":"3.70841"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2542","spread":"1.75414"},{"groupId":"OG001","value":"0.6661","spread":"1.44582"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0886","spread":"2.99912"},{"groupId":"OG001","value":"1.4155","spread":"3.15690"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0956","spread":"1.98021"},{"groupId":"OG001","value":"0.2405","spread":"1.85063"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4539","spread":"1.53147"},{"groupId":"OG001","value":"0.2035","spread":"2.89966"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1437","spread":"2.20744"},{"groupId":"OG001","value":"0.5644","spread":"1.44173"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1457","spread":"1.83254"},{"groupId":"OG001","value":"-0.2683","spread":"1.26456"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1596","spread":"1.85981"},{"groupId":"OG001","value":"-1.4766","spread":"2.48794"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4788","spread":"1.91895"},{"groupId":"OG001","value":"-0.0999","spread":"3.18721"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4084","spread":"2.50478"},{"groupId":"OG001","value":"-0.1554","spread":"4.07581"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1565","spread":"1.79106"},{"groupId":"OG001","value":"-1.5959","spread":"2.23900"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Lipase Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in lipase levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":"108.56"},{"groupId":"OG001","value":"48.3","spread":"55.19"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":"43.77"},{"groupId":"OG001","value":"3.3","spread":"3.21"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.5","spread":"34.95"},{"groupId":"OG001","value":"9.3","spread":"13.58"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.4","spread":"36.77"},{"groupId":"OG001","value":"0.0","spread":"1.73"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.4","spread":"64.01"},{"groupId":"OG001","value":"18.0","spread":"25.36"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.5","spread":"63.33"},{"groupId":"OG001","value":"-6.7","spread":"22.74"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.3","spread":"91.54"},{"groupId":"OG001","value":"-10.7","spread":"37.87"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"99.60"},{"groupId":"OG001","value":"9.3","spread":"16.92"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"100.78"},{"groupId":"OG001","value":"37.0","spread":"28.16"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":"44.42"},{"groupId":"OG001","value":"19.7","spread":"100.17"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":"38.25"},{"groupId":"OG001","value":"-15.0","spread":"84.85"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"35.42"},{"groupId":"OG001","value":"0.0","spread":"31.00"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Magnesium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in magnesium levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8969","spread":"0.19546"},{"groupId":"OG001","value":"0.8607","spread":"0.14418"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0219","spread":"0.11853"},{"groupId":"OG001","value":"-0.0441","spread":"0.06638"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0194","spread":"0.14406"},{"groupId":"OG001","value":"-0.0319","spread":"0.11737"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0430","spread":"0.11666"},{"groupId":"OG001","value":"-0.0167","spread":"0.12869"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0374","spread":"0.17268"},{"groupId":"OG001","value":"0.0304","spread":"0.16521"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0151","spread":"0.22358"},{"groupId":"OG001","value":"0.0754","spread":"0.10859"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0348","spread":"0.18742"},{"groupId":"OG001","value":"0.0534","spread":"0.13315"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0151","spread":"0.21498"},{"groupId":"OG001","value":"0.0519","spread":"0.15865"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0435","spread":"0.15736"},{"groupId":"OG001","value":"-0.0811","spread":"0.16860"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0645","spread":"0.15320"},{"groupId":"OG001","value":"-0.0494","spread":"0.09381"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0564","spread":"0.19263"},{"groupId":"OG001","value":"-0.1264","spread":"0.15097"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1484","spread":"0.28794"},{"groupId":"OG001","value":"-0.0608","spread":"0.08902"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Potassium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in potassium levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.76","spread":"0.439"},{"groupId":"OG001","value":"3.87","spread":"0.301"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.515"},{"groupId":"OG001","value":"-0.03","spread":"0.242"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"0.717"},{"groupId":"OG001","value":"-0.10","spread":"0.329"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.788"},{"groupId":"OG001","value":"-0.37","spread":"1.117"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.651"},{"groupId":"OG001","value":"0.22","spread":"0.601"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.446"},{"groupId":"OG001","value":"0.35","spread":"0.497"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.542"},{"groupId":"OG001","value":"0.37","spread":"0.582"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.578"},{"groupId":"OG001","value":"0.75","spread":"0.946"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.585"},{"groupId":"OG001","value":"0.10","spread":"0.255"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.734"},{"groupId":"OG001","value":"0.42","spread":"0.657"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.654"},{"groupId":"OG001","value":"0.32","spread":"0.683"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.442"},{"groupId":"OG001","value":"0.38","spread":"0.741"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Protein Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in protein levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":"9.91"},{"groupId":"OG001","value":"52.2","spread":"7.52"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.71"},{"groupId":"OG001","value":"1.0","spread":"5.51"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.34"},{"groupId":"OG001","value":"1.5","spread":"5.92"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"4.08"},{"groupId":"OG001","value":"4.0","spread":"6.69"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"4.10"},{"groupId":"OG001","value":"6.5","spread":"5.99"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"2.96"},{"groupId":"OG001","value":"8.8","spread":"7.41"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"5.05"},{"groupId":"OG001","value":"6.3","spread":"5.89"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"4.87"},{"groupId":"OG001","value":"7.5","spread":"5.05"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"5.06"},{"groupId":"OG001","value":"5.6","spread":"5.68"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"9.21"},{"groupId":"OG001","value":"11.0","spread":"6.44"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"10.18"},{"groupId":"OG001","value":"16.5","spread":"8.19"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"11.56"},{"groupId":"OG001","value":"20.0","spread":"7.21"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Serum Chemistry Parameter: Sodium Levels","description":"Serum chemistry measures included alanine aminotransferase, albumin, aspartate aminotransferase, bicarbonate, bilirubin, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, glucose, lipase, magnesium, potassium, protein, sodium. CFB in sodium levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140.6","spread":"4.84"},{"groupId":"OG001","value":"141.7","spread":"4.84"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.87"},{"groupId":"OG001","value":"-3.8","spread":"4.12"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"4.31"},{"groupId":"OG001","value":"0.3","spread":"5.72"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"3.88"},{"groupId":"OG001","value":"1.7","spread":"6.19"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"3.50"},{"groupId":"OG001","value":"1.5","spread":"3.94"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"4.80"},{"groupId":"OG001","value":"-0.5","spread":"4.04"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"5.12"},{"groupId":"OG001","value":"-1.0","spread":"4.60"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"5.64"},{"groupId":"OG001","value":"0.2","spread":"5.85"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"5.65"},{"groupId":"OG001","value":"0.0","spread":"5.79"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"5.51"},{"groupId":"OG001","value":"-0.4","spread":"7.64"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"5.53"},{"groupId":"OG001","value":"-3.2","spread":"4.32"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"6.34"},{"groupId":"OG001","value":"-4.5","spread":"1.29"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Basophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophil levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells per microliter(10^3 cells/uL)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.031","spread":"0.0509"},{"groupId":"OG001","value":"0.037","spread":"0.0321"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":"0.0308"},{"groupId":"OG001","value":"0.003","spread":"0.0058"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.008","spread":"0.0319"},{"groupId":"OG001","value":"-0.023","spread":"0.0321"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.0230"},{"groupId":"OG001","value":"-0.007","spread":"0.0208"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":"0.0433"},{"groupId":"OG001","value":"-0.013","spread":"0.0115"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.0662"},{"groupId":"OG001","value":"-0.010","spread":"0.0141"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.033","spread":"0.0369"},{"groupId":"OG001","value":"0.087","spread":"0.1848"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.006","spread":"0.0669"},{"groupId":"OG001","value":"-0.017","spread":"0.0153"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":"0.0745"},{"groupId":"OG001","value":"-0.017","spread":"0.0153"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.031","spread":"0.0366"},{"groupId":"OG001","value":"0.040","spread":"0.0849"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.0216"},{"groupId":"OG001","value":"0.000"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.017","spread":"0.0288"},{"groupId":"OG001","value":"-0.005","spread":"0.0071"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Basophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in basophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","populationDescription":"Safety Population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of cells","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.707"},{"groupId":"OG001","value":"0.00","spread":"0.000"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.707"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.707"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.707"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.000"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Eosinophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3364","spread":"0.42711"},{"groupId":"OG001","value":"0.7433","spread":"0.20108"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0580","spread":"0.17813"},{"groupId":"OG001","value":"-0.2700","spread":"0.24269"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0660","spread":"0.23538"},{"groupId":"OG001","value":"-0.2333","spread":"0.45654"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0911","spread":"0.35069"},{"groupId":"OG001","value":"-0.6467","spread":"0.14189"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0811","spread":"0.36381"},{"groupId":"OG001","value":"-0.5867","spread":"0.07095"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1878","spread":"0.45535"},{"groupId":"OG001","value":"-0.4200","spread":"0.41940"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2211","spread":"0.44552"},{"groupId":"OG001","value":"-0.5567","spread":"0.16258"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1643","spread":"0.42177"},{"groupId":"OG001","value":"-0.5567","spread":"0.17898"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1056","spread":"0.40423"},{"groupId":"OG001","value":"-0.5400","spread":"0.17776"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0078","spread":"0.33774"},{"groupId":"OG001","value":"0.0100","spread":"0.26870"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0543","spread":"0.42496"},{"groupId":"OG001","value":"-0.3000"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0229","spread":"0.39982"},{"groupId":"OG001","value":"-0.5650","spread":"0.33234"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Eosinophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in eosinophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of cells","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":"0.000"},{"groupId":"OG001","value":"3.00","spread":"0.000"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.00"},{"groupId":"OG001","value":"-2.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.707"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"2.121"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.707"},{"groupId":"OG001","value":"-2.00"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.000"},{"groupId":"OG001","value":"-2.00"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"0.707"},{"groupId":"OG001","value":"-3.00"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"1.414"},{"groupId":"OG001","value":"-3.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"2.121"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"1.414"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"2.828"},{"groupId":"OG001","value":"-1.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.707"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Concentration Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin concentration levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"328.4","spread":"12.54"},{"groupId":"OG001","value":"322.6","spread":"12.54"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.52"},{"groupId":"OG001","value":"1.0","spread":"5.66"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"10.43"},{"groupId":"OG001","value":"10.4","spread":"12.18"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"7.88"},{"groupId":"OG001","value":"5.4","spread":"6.19"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"10.00"},{"groupId":"OG001","value":"3.6","spread":"6.35"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"9.33"},{"groupId":"OG001","value":"1.8","spread":"3.03"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"10.65"},{"groupId":"OG001","value":"-0.4","spread":"2.61"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"10.44"},{"groupId":"OG001","value":"0.4","spread":"5.50"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"11.07"},{"groupId":"OG001","value":"-2.3","spread":"9.54"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"14.28"},{"groupId":"OG001","value":"-0.5","spread":"13.77"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"18.40"},{"groupId":"OG001","value":"11.5","spread":"32.25"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"16.10"},{"groupId":"OG001","value":"-9.3","spread":"7.50"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular hemoglobin levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"femtomoles (fmol)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8611","spread":"0.17564"},{"groupId":"OG001","value":"1.8335","spread":"0.09869"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0110","spread":"0.04180"},{"groupId":"OG001","value":"-0.0149","spread":"0.02996"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0134","spread":"0.03603"},{"groupId":"OG001","value":"0.0261","spread":"0.09580"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0097","spread":"0.03719"},{"groupId":"OG001","value":"0.0074","spread":"0.03911"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0107","spread":"0.04378"},{"groupId":"OG001","value":"-0.0099","spread":"0.02177"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0164","spread":"0.04034"},{"groupId":"OG001","value":"0.0112","spread":"0.03147"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0194","spread":"0.03684"},{"groupId":"OG001","value":"0.0099","spread":"0.03582"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0112","spread":"0.04763"},{"groupId":"OG001","value":"0.0161","spread":"0.03662"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0058","spread":"0.04491"},{"groupId":"OG001","value":"0.0155","spread":"0.04927"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0087","spread":"0.09182"},{"groupId":"OG001","value":"0.0310","spread":"0.07868"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0306","spread":"0.14055"},{"groupId":"OG001","value":"0.0729","spread":"0.14436"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0412","spread":"0.11506"},{"groupId":"OG001","value":"0.0341","spread":"0.07457"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"femtoliters (fL)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.36","spread":"7.651"},{"groupId":"OG001","value":"91.50","spread":"4.785"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"1.773"},{"groupId":"OG001","value":"-0.42","spread":"0.950"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"2.202"},{"groupId":"OG001","value":"-0.82","spread":"1.487"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"2.168"},{"groupId":"OG001","value":"-1.12","spread":"1.314"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"2.202"},{"groupId":"OG001","value":"-1.04","spread":"1.146"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"2.560"},{"groupId":"OG001","value":"0.10","spread":"1.954"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"2.362"},{"groupId":"OG001","value":"0.76","spread":"1.977"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"3.270"},{"groupId":"OG001","value":"0.36","spread":"1.230"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":"3.507"},{"groupId":"OG001","value":"1.08","spread":"1.090"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"4.337"},{"groupId":"OG001","value":"2.25","spread":"4.124"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"5.675"},{"groupId":"OG001","value":"0.75","spread":"3.747"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"5.315"},{"groupId":"OG001","value":"4.27","spread":"1.775"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Erythrocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in erythrocyte levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^6 cells per microliter","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.261","spread":"0.7152"},{"groupId":"OG001","value":"3.406","spread":"0.5297"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.078","spread":"0.3236"},{"groupId":"OG001","value":"-0.022","spread":"0.1816"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.106","spread":"0.4059"},{"groupId":"OG001","value":"-0.184","spread":"0.2799"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.162","spread":"0.4112"},{"groupId":"OG001","value":"-0.218","spread":"0.2072"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.175","spread":"0.4261"},{"groupId":"OG001","value":"-0.132","spread":"0.3041"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.152","spread":"0.3718"},{"groupId":"OG001","value":"-0.158","spread":"0.5079"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.259","spread":"0.4001"},{"groupId":"OG001","value":"-0.256","spread":"0.5786"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.199","spread":"0.3819"},{"groupId":"OG001","value":"-0.200","spread":"0.7139"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.196","spread":"0.4508"},{"groupId":"OG001","value":"-0.463","spread":"0.4367"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.115","spread":"0.7317"},{"groupId":"OG001","value":"-0.133","spread":"0.5821"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.285","spread":"0.9424"},{"groupId":"OG001","value":"0.105","spread":"0.3493"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.607","spread":"0.4754"},{"groupId":"OG001","value":"0.248","spread":"0.2924"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Hematocrit Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hematocrit levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"proportion of 1.0 (in liters)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2955","spread":"0.05601"},{"groupId":"OG001","value":"0.3110","spread":"0.05443"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0042","spread":"0.02561"},{"groupId":"OG001","value":"-0.0028","spread":"0.01591"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0058","spread":"0.03430"},{"groupId":"OG001","value":"-0.0192","spread":"0.02013"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0123","spread":"0.03371"},{"groupId":"OG001","value":"-0.0238","spread":"0.01487"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0131","spread":"0.03564"},{"groupId":"OG001","value":"-0.0142","spread":"0.02860"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0108","spread":"0.03167"},{"groupId":"OG001","value":"-0.0160","spread":"0.04813"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0209","spread":"0.03369"},{"groupId":"OG001","value":"-0.0238","spread":"0.05369"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0135","spread":"0.03487"},{"groupId":"OG001","value":"-0.0182","spread":"0.06883"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0142","spread":"0.03823"},{"groupId":"OG001","value":"-0.0375","spread":"0.04888"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0143","spread":"0.05903"},{"groupId":"OG001","value":"-0.0058","spread":"0.05967"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0188","spread":"0.06186"},{"groupId":"OG001","value":"0.0128","spread":"0.03157"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0516","spread":"0.04241"},{"groupId":"OG001","value":"0.0370","spread":"0.02670"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Hemoglobin Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in hemoglobin levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/L","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.3","spread":"19.93"},{"groupId":"OG001","value":"100.4","spread":"18.28"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"9.96"},{"groupId":"OG001","value":"-0.8","spread":"5.26"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"11.81"},{"groupId":"OG001","value":"-3.4","spread":"4.77"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"12.37"},{"groupId":"OG001","value":"-5.8","spread":"4.21"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"12.89"},{"groupId":"OG001","value":"-4.0","spread":"7.97"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"11.54"},{"groupId":"OG001","value":"-4.4","spread":"14.99"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":"12.69"},{"groupId":"OG001","value":"-7.2","spread":"16.75"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"12.78"},{"groupId":"OG001","value":"-5.6","spread":"20.67"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"14.41"},{"groupId":"OG001","value":"-12.3","spread":"12.97"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"22.10"},{"groupId":"OG001","value":"-2.0","spread":"18.65"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"21.36"},{"groupId":"OG001","value":"8.3","spread":"12.58"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"14.50"},{"groupId":"OG001","value":"9.5","spread":"9.26"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Leukocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in leukocyte levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.383","spread":"4.3503"},{"groupId":"OG001","value":"16.538","spread":"8.5348"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.438","spread":"2.5891"},{"groupId":"OG001","value":"-0.902","spread":"2.4833"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.186","spread":"4.5526"},{"groupId":"OG001","value":"-3.306","spread":"4.7047"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.227","spread":"6.1765"},{"groupId":"OG001","value":"-3.090","spread":"5.5029"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.577","spread":"7.1508"},{"groupId":"OG001","value":"-3.798","spread":"5.5846"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.591","spread":"10.3636"},{"groupId":"OG001","value":"-3.964","spread":"5.3646"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.002","spread":"8.9938"},{"groupId":"OG001","value":"-1.306","spread":"7.5940"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.123","spread":"10.4153"},{"groupId":"OG001","value":"-1.652","spread":"7.3674"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.145","spread":"7.3294"},{"groupId":"OG001","value":"-2.188","spread":"6.7041"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.692","spread":"5.0282"},{"groupId":"OG001","value":"-6.118","spread":"7.0178"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.132","spread":"4.3853"},{"groupId":"OG001","value":"-7.248","spread":"7.3886"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.790","spread":"6.1582"},{"groupId":"OG001","value":"-5.840","spread":"4.6825"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Lymphocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocyte levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.791","spread":"0.8043"},{"groupId":"OG001","value":"2.323","spread":"0.5193"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.213","spread":"0.8923"},{"groupId":"OG001","value":"-0.470","spread":"0.2427"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.189","spread":"1.3559"},{"groupId":"OG001","value":"-1.147","spread":"0.9771"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.302","spread":"1.0584"},{"groupId":"OG001","value":"-0.640","spread":"1.1037"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.200","spread":"1.1580"},{"groupId":"OG001","value":"-0.780","spread":"0.4358"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.428","spread":"1.1946"},{"groupId":"OG001","value":"-0.777","spread":"0.6516"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.152","spread":"0.9193"},{"groupId":"OG001","value":"-0.987","spread":"1.0040"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.360","spread":"0.8965"},{"groupId":"OG001","value":"-1.013","spread":"0.8799"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.482","spread":"0.8724"},{"groupId":"OG001","value":"-0.700","spread":"0.6720"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.392","spread":"0.8363"},{"groupId":"OG001","value":"-1.140","spread":"0.9334"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.343","spread":"0.6667"},{"groupId":"OG001","value":"-2.200"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.427","spread":"0.8182"},{"groupId":"OG001","value":"-0.845","spread":"1.0677"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Lymphocytes to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in lymphocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of cells","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.67","spread":"7.024"},{"groupId":"OG001","value":"6.50","spread":"7.778"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.000"},{"groupId":"OG001","value":"4.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"2.121"},{"groupId":"OG001","value":"8.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"5.033"},{"groupId":"OG001","value":"10.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"4.950"},{"groupId":"OG001","value":"6.00"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.50","spread":"6.364"},{"groupId":"OG001","value":"8.00"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.00","spread":"4.243"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.00","spread":"2.828"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.00","spread":"1.414"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"3.536"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.00","spread":"4.243"},{"groupId":"OG001","value":"11.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"2.121"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Monocyte Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocyte levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6182","spread":"0.26966"},{"groupId":"OG001","value":"1.2567","spread":"0.83584"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2720","spread":"0.39137"},{"groupId":"OG001","value":"0.3470","spread":"0.83703"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2830","spread":"0.54878"},{"groupId":"OG001","value":"-0.1200","spread":"1.05399"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1267","spread":"0.52906"},{"groupId":"OG001","value":"-0.0667","spread":"0.06110"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2978","spread":"0.44409"},{"groupId":"OG001","value":"0.4533","spread":"0.39068"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2322","spread":"0.42364"},{"groupId":"OG001","value":"0.1300","spread":"0.96016"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2856","spread":"0.47710"},{"groupId":"OG001","value":"-0.1400","spread":"0.34176"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2800","spread":"0.39418"},{"groupId":"OG001","value":"-0.4533","spread":"0.36295"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1900","spread":"0.24850"},{"groupId":"OG001","value":"-0.2400","spread":"0.72194"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1767","spread":"0.41602"},{"groupId":"OG001","value":"-0.1100","spread":"1.99404"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.3029","spread":"0.63746"},{"groupId":"OG001","value":"1.7000"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0414","spread":"0.21396"},{"groupId":"OG001","value":"0.4850","spread":"0.44548"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Monocytes to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in monocytes to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of cells","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.67","spread":"5.508"},{"groupId":"OG001","value":"5.00","spread":"4.243"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"0.000"},{"groupId":"OG001","value":"1.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"7.778"},{"groupId":"OG001","value":"13.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"0.577"},{"groupId":"OG001","value":"15.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.50","spread":"4.950"},{"groupId":"OG001","value":"8.00"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.50","spread":"9.192"},{"groupId":"OG001","value":"8.00"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.50","spread":"9.192"},{"groupId":"OG001","value":"-1.00"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-7.00","spread":"9.899"},{"groupId":"OG001","value":"-2.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.00","spread":"8.485"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.50","spread":"6.364"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"4.950"},{"groupId":"OG001","value":"0.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.50","spread":"9.192"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Neutrophil Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophil levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.957","spread":"4.1505"},{"groupId":"OG001","value":"13.863","spread":"8.8017"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.152","spread":"2.4078"},{"groupId":"OG001","value":"-0.043","spread":"1.7435"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.552","spread":"3.1815"},{"groupId":"OG001","value":"-0.783","spread":"2.9957"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.406","spread":"3.4517"},{"groupId":"OG001","value":"-0.167","spread":"7.0002"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.727","spread":"3.6351"},{"groupId":"OG001","value":"-1.620","spread":"6.0920"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.743","spread":"3.3970"},{"groupId":"OG001","value":"-2.653","spread":"5.7315"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.848","spread":"4.2871"},{"groupId":"OG001","value":"-4.247","spread":"6.7336"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.440","spread":"4.1338"},{"groupId":"OG001","value":"-3.517","spread":"7.8465"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.731","spread":"4.4360"},{"groupId":"OG001","value":"-1.953","spread":"7.7993"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.372","spread":"4.3518"},{"groupId":"OG001","value":"-9.825","spread":"6.9650"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.877","spread":"3.2310"},{"groupId":"OG001","value":"-10.645","spread":"7.9832"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.590","spread":"2.6196"},{"groupId":"OG001","value":"-6.323","spread":"3.8800"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Neutrophils to Leukocytes Ratio Reported in Percentage of Cells","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in neutrophils to leukocytes ratio is reported in terms of percentage of cells in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"percentage of cells","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.67","spread":"11.240"},{"groupId":"OG001","value":"71.00","spread":"8.485"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"9.192"},{"groupId":"OG001","value":"19.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","spread":"5.657"},{"groupId":"OG001","value":"6.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":"10.504"},{"groupId":"OG001","value":"3.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.00","spread":"11.314"},{"groupId":"OG001","value":"2.00"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.50","spread":"17.678"},{"groupId":"OG001","value":"9.00"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.00","spread":"14.142"},{"groupId":"OG001","value":"31.00"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.00","spread":"8.485"},{"groupId":"OG001","value":"25.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.00","spread":"11.314"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"9.192"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.00","spread":"7.071"},{"groupId":"OG001","value":"-10.00"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.50","spread":"14.849"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hematology Parameter: Platelet Levels","description":"Hematology measures included basophils, basophils to leukocytes ratio, eosinophils, eosinophils to leukocytes ratio, erythrocytes mean corpuscular hemoglobin concentration, erythrocytes mean corpuscular hemoglobin, erythrocytes mean corpuscular volume, erythrocytes, hematocrit, hemoglobin, leukocytes, lymphocytes, lymphocytes to leukocytes ratio, monocytes, monocytes to leukocytes ratio, neutrophils, neutrophils to leukocytes ratio, platelets. CFB in platelet levels is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^3 cells/uL","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"260.76","spread":"95.417"},{"groupId":"OG001","value":"284.20","spread":"80.707"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"68.821"},{"groupId":"OG001","value":"21.40","spread":"40.265"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.38","spread":"92.854"},{"groupId":"OG001","value":"34.40","spread":"69.263"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.59","spread":"109.995"},{"groupId":"OG001","value":"58.00","spread":"95.533"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.92","spread":"112.963"},{"groupId":"OG001","value":"77.80","spread":"89.461"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"57.49","spread":"125.277"},{"groupId":"OG001","value":"64.80","spread":"101.043"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.04","spread":"138.415"},{"groupId":"OG001","value":"61.80","spread":"106.767"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.98","spread":"141.650"},{"groupId":"OG001","value":"50.80","spread":"130.555"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.33","spread":"120.436"},{"groupId":"OG001","value":"48.75","spread":"136.231"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"153.89","spread":"166.919"},{"groupId":"OG001","value":"87.25","spread":"177.265"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.35","spread":"204.827"},{"groupId":"OG001","value":"49.75","spread":"75.292"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.76","spread":"118.996"},{"groupId":"OG001","value":"56.75","spread":"112.512"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate","description":"ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in heart rate is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats/min","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":"13.31"},{"groupId":"OG001","value":"84.3","spread":"19.64"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"16.87"},{"groupId":"OG001","value":"-6.8","spread":"8.54"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"16.58"},{"groupId":"OG001","value":"-1.2","spread":"6.85"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"21.74"},{"groupId":"OG001","value":"-6.5","spread":"22.28"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"15.49"},{"groupId":"OG001","value":"7.7","spread":"18.48"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"15.37"},{"groupId":"OG001","value":"7.0","spread":"19.62"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"14.25"},{"groupId":"OG001","value":"11.7","spread":"22.76"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"16.91"},{"groupId":"OG001","value":"17.0","spread":"26.47"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"16.00"},{"groupId":"OG001","value":"5.5","spread":"22.87"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":"23.09"},{"groupId":"OG001","value":"5.5","spread":"13.13"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":"20.71"},{"groupId":"OG001","value":"4.3","spread":"26.73"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"13.60"},{"groupId":"OG001","value":"7.0","spread":"31.19"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Interval, QT Interval and QTc Interval","description":"ECG measures included heart rate, PR interval, QT interval, QRS duration and QTc interval. CFB in PR interval, QT interval, QRS duration and QTc interval is reported in this outcome measure.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"milliseconds (msec)","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"PR interval: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"151.0","lowerLimit":"118","upperLimit":"192"},{"groupId":"OG001","value":"151.0","lowerLimit":"132","upperLimit":"182"}]}]},{"title":"PR interval: CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-40","upperLimit":"10"},{"groupId":"OG001","value":"-2.0","lowerLimit":"-16","upperLimit":"18"}]}]},{"title":"PR interval: CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"-40","upperLimit":"148"},{"groupId":"OG001","value":"3.0","lowerLimit":"-4","upperLimit":"15"}]}]},{"title":"PR interval: CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","lowerLimit":"-42","upperLimit":"16"},{"groupId":"OG001","value":"-2.0","lowerLimit":"-8","upperLimit":"18"}]}]},{"title":"PR interval: CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-22","upperLimit":"22"},{"groupId":"OG001","value":"-4.0","lowerLimit":"-6","upperLimit":"7"}]}]},{"title":"PR interval: CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","lowerLimit":"-32","upperLimit":"68"},{"groupId":"OG001","value":"2.0","lowerLimit":"-22","upperLimit":"26"}]}]},{"title":"PR interval: CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.0","lowerLimit":"-25","upperLimit":"23"},{"groupId":"OG001","value":"3.5","lowerLimit":"-28","upperLimit":"12"}]}]},{"title":"PR interval: CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","lowerLimit":"-38","upperLimit":"14"},{"groupId":"OG001","value":"-2.0","lowerLimit":"-26","upperLimit":"24"}]}]},{"title":"PR interval: CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","lowerLimit":"-30","upperLimit":"4"},{"groupId":"OG001","value":"0.0","lowerLimit":"-20","upperLimit":"2"}]}]},{"title":"PR interval: CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-54","upperLimit":"26"},{"groupId":"OG001","value":"4.0","lowerLimit":"-16","upperLimit":"18"}]}]},{"title":"PR interval: CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-26","upperLimit":"36"},{"groupId":"OG001","value":"-6.5","lowerLimit":"-40","upperLimit":"10"}]}]},{"title":"PR interval: CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-20","upperLimit":"14"},{"groupId":"OG001","value":"-8.0","lowerLimit":"-18","upperLimit":"22"}]}]},{"title":"QRS Interval: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","lowerLimit":"66","upperLimit":"118"},{"groupId":"OG001","value":"78.0","lowerLimit":"40","upperLimit":"100"}]}]},{"title":"QRS Interval: CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"-12","upperLimit":"14"},{"groupId":"OG001","value":"1.5","lowerLimit":"-4","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-14","upperLimit":"40"},{"groupId":"OG001","value":"-1.0","lowerLimit":"-8","upperLimit":"6"}]}]},{"title":"QRS Interval: CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","lowerLimit":"-20","upperLimit":"6"},{"groupId":"OG001","value":"2.0","lowerLimit":"-2","upperLimit":"5"}]}]},{"title":"QRS Interval: CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"-16","upperLimit":"18"},{"groupId":"OG001","value":"0.0","lowerLimit":"-6","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","lowerLimit":"-32","upperLimit":"14"},{"groupId":"OG001","value":"0.0","lowerLimit":"-14","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-32","upperLimit":"8"},{"groupId":"OG001","value":"0.0","lowerLimit":"-14","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","lowerLimit":"-28","upperLimit":"16"},{"groupId":"OG001","value":"-3.0","lowerLimit":"-94","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-28","upperLimit":"0"},{"groupId":"OG001","value":"-3.5","lowerLimit":"-16","upperLimit":"0"}]}]},{"title":"QRS Interval: CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","lowerLimit":"-47","upperLimit":"6"},{"groupId":"OG001","value":"2.0","lowerLimit":"-2","upperLimit":"40"}]}]},{"title":"QRS Interval: CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","lowerLimit":"-26","upperLimit":"6"},{"groupId":"OG001","value":"-1.0","lowerLimit":"-4","upperLimit":"20"}]}]},{"title":"QRS Interval: CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-26","upperLimit":"12"},{"groupId":"OG001","value":"5.0","lowerLimit":"-4","upperLimit":"40"}]}]},{"title":"QT Interval: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"363.0","lowerLimit":"304","upperLimit":"476"},{"groupId":"OG001","value":"372.0","lowerLimit":"280","upperLimit":"462"}]}]},{"title":"QT Interval: CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"-84","upperLimit":"200"},{"groupId":"OG001","value":"24.5","lowerLimit":"-26","upperLimit":"49"}]}]},{"title":"QT Interval: CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","lowerLimit":"-102","upperLimit":"236"},{"groupId":"OG001","value":"3.0","lowerLimit":"-40","upperLimit":"30"}]}]},{"title":"QT Interval: CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","lowerLimit":"-168","upperLimit":"238"},{"groupId":"OG001","value":"-14.0","lowerLimit":"-66","upperLimit":"144"}]}]},{"title":"QT Interval: CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","lowerLimit":"-62","upperLimit":"128"},{"groupId":"OG001","value":"0.0","lowerLimit":"-76","upperLimit":"118"}]}]},{"title":"QT Interval: CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-34.0","lowerLimit":"-164","upperLimit":"72"},{"groupId":"OG001","value":"-36.0","lowerLimit":"-102","upperLimit":"66"}]}]},{"title":"QT Interval: CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-28.0","lowerLimit":"-168","upperLimit":"238"},{"groupId":"OG001","value":"-32.0","lowerLimit":"-126","upperLimit":"40"}]}]},{"title":"QT Interval: CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-32.0","lowerLimit":"-164","upperLimit":"74"},{"groupId":"OG001","value":"-34.0","lowerLimit":"-156","upperLimit":"18"}]}]},{"title":"QT Interval: CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-36.0","lowerLimit":"-186","upperLimit":"42"},{"groupId":"OG001","value":"-35.0","lowerLimit":"-138","upperLimit":"-6"}]}]},{"title":"QT Interval: CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-32.0","lowerLimit":"-176","upperLimit":"72"},{"groupId":"OG001","value":"-8.0","lowerLimit":"-116","upperLimit":"16"}]}]},{"title":"QT Interval: CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-28.0","lowerLimit":"-132","upperLimit":"51"},{"groupId":"OG001","value":"-22.0","lowerLimit":"-102","upperLimit":"24"}]}]},{"title":"QT Interval: CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-28.0","lowerLimit":"-132","upperLimit":"29"},{"groupId":"OG001","value":"-63.0","lowerLimit":"-96","upperLimit":"80"}]}]},{"title":"QTc Interval: Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"435.5","lowerLimit":"321","upperLimit":"531"},{"groupId":"OG001","value":"438.5","lowerLimit":"393","upperLimit":"454"}]}]},{"title":"QTc Interval: CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"-55","upperLimit":"219"},{"groupId":"OG001","value":"7.0","lowerLimit":"-58","upperLimit":"42"}]}]},{"title":"QTc Interval: CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","lowerLimit":"-49","upperLimit":"277"},{"groupId":"OG001","value":"-12.5","lowerLimit":"-59","upperLimit":"29"}]}]},{"title":"QTc Interval: CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"-103","upperLimit":"275"},{"groupId":"OG001","value":"-14.0","lowerLimit":"-38","upperLimit":"36"}]}]},{"title":"QTc Interval: CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"-30","upperLimit":"145"},{"groupId":"OG001","value":"-13.5","lowerLimit":"-41","upperLimit":"152"}]}]},{"title":"QTc Interval: CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-88","upperLimit":"106"},{"groupId":"OG001","value":"-17.0","lowerLimit":"-38","upperLimit":"43"}]}]},{"title":"QTc Interval: CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","lowerLimit":"-87","upperLimit":"319"},{"groupId":"OG001","value":"-9.0","lowerLimit":"-31","upperLimit":"10"}]}]},{"title":"QTc Interval: CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","lowerLimit":"-96","upperLimit":"93"},{"groupId":"OG001","value":"-17.5","lowerLimit":"-52","upperLimit":"15"}]}]},{"title":"QTc Interval: CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","lowerLimit":"-111","upperLimit":"83"},{"groupId":"OG001","value":"-54.5","lowerLimit":"-86","upperLimit":"14"}]}]},{"title":"QTc Interval: CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"-104","upperLimit":"71"},{"groupId":"OG001","value":"-6.5","lowerLimit":"-50","upperLimit":"3"}]}]},{"title":"QTc Interval: CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","lowerLimit":"-57","upperLimit":"51"},{"groupId":"OG001","value":"-33.5","lowerLimit":"-37","upperLimit":"-14"}]}]},{"title":"QTc Interval: CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-72","upperLimit":"51"},{"groupId":"OG001","value":"-19.0","lowerLimit":"-51","upperLimit":"23"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Prior Anti-epileptic Drugs (AEDs) and Pressors Usage","description":"Prior AEDs and Pressors are those medications that ended before the initiation of SAGE-547 infusion.","populationDescription":"Safety population included all participants who were initiated with an infusion of SAGE-547.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Relapse - Re-Initiation of Third-Line Agent","description":"Relapse of participants is defined as successfully weaning from a continuous IV third-line agent but subsequent requirement of re-initiation of a third-line agent following conclusion of SAGE-547 treatment.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Response (Treatment Responders)","description":"A responder was defined as a participant for whom it was not required to re-initiate continuous IV third-line therapy for refractory seizure control during the administration of SAGE-547 at the maintenance dose (prior to SAGE-547 taper infusion).","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 96 hours","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response was defined as the time from the stop date/time of SAGE-547 maintenance to re-initiation of a third-line agent. If no re-initiation of a third-line agent was required, duration of response was not estimable and censored at Day 29 or death date, whichever occurred first. Kaplan-Meier method was used for the analysis.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"Up to Day 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and confidence interval were not calculable due to more than 50% censored participants (8) in this treatment group."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median and confidence interval were not calculable due to more than 50% censored participants (3) in this treatment group."}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) of SAGE-547","populationDescription":"Pharmacokinetic (PK) population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.24","spread":"65.263"},{"groupId":"OG001","value":"200.82","spread":"71.000"}]}]}]},{"type":"SECONDARY","title":"Time to Attain Maximum Observed Plasma Concentration (Tmax) of SAGE-547","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.010","lowerLimit":"0.92","upperLimit":"96.00"},{"groupId":"OG001","value":"60.150","lowerLimit":"0.93","upperLimit":"118.52"}]}]}]},{"type":"SECONDARY","title":"Areas Under the Plasma SAGE-547 Concentration Time Curves From the Start of the Infusion Until the Time to the Last Sample (AUClast)","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hour*nanograms per milliliter (h*ng/mL)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7677.6","spread":"2668.06"},{"groupId":"OG001","value":"14260.0","spread":"5048.01"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma SAGE-547 Concentration-Time Curve in a 24 Hour Period (AUC24)","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"h*ng/mL","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8 and 24 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1590.3","spread":"524.58"},{"groupId":"OG001","value":"2728.3","spread":"1010.14"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma SAGE-547 Concentration-Time Curve (AUC1-96)","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"h*ng/mL","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6290.6","spread":"2080.04"},{"groupId":"OG001","value":"10801.7","spread":"4006.70"}]}]}]},{"type":"SECONDARY","title":"Average Plasma Concentration (Cav) of SAGE-547","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72 and 96 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.22","spread":"21.929"},{"groupId":"OG001","value":"113.62","spread":"42.079"}]}]}]},{"type":"SECONDARY","title":"Plasma Clearance (CL) of SAGE-547","description":"Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.","populationDescription":"PK population included all participants who received the study drug and had at least one PK sample taken. Overall number of participants analyzed is the number of participants with data available for analysis at the given time point for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"liters per hour per kilogram (L/h/kg)","timeFrame":"Pre-dose (0 hours), 1, 2, 4, 8, 24, 48, 72, 96, 104, 112, 120 and 144 hours post-dose","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3999","spread":"0.54525"},{"groupId":"OG001","value":"1.2487","spread":"0.65351"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Rankin Scale (mRS-9Q) Scores","description":"The mRS-9Q is a commonly used scale to determine disability and functional dependence due to neurological insult such as a stroke. It is a shortened version consisting of 9 questions. The score was categorized on the scale of 0 to 5 (0 = No symptoms, 1 = No significant disability, able to carry out all usual activities, despite some symptoms, 2 = Slight disability, able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability, requires some help, but able to walk unassisted, 4 = Moderately severe disability, unable to attend to own bodily needs without assistance or unable to walk unassisted, and 5 = Severe disability, requires constant nursing care and attention, bedridden). Higher scores indicated worsening of symptoms.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline (Screening) to Infusion at 49-72 hour, 73-96 hour; Extended follow-up at Day 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"0.00"},{"groupId":"OG001","value":"5.0","spread":"0.00"}]}]},{"title":"CBF at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"},{"groupId":"OG001","value":"0.0","spread":"0.00"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.00"},{"groupId":"OG001","value":"0.0","spread":"0.00"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.26"},{"groupId":"OG001","value":"0.0","spread":"0.00"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.35"},{"groupId":"OG001","value":"-0.3","spread":"0.50"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.74"},{"groupId":"OG001","value":"-0.5","spread":"0.58"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.50"},{"groupId":"OG001","value":"-1.0","spread":"1.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression: Severity Scale (CGI-S)","description":"The CGI-Severity (CGI-S) scale employs a 7-point Likert scale to assess the severity of participant's current illness state. Clinician responded to a question \"Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?\" on the following scores: 1 = Normal, not at all ill, 2 = Borderline ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill, where higher score = more affected.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline (Screening), Extended follow-up at Days 8, 15, 22, and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"0.25"},{"groupId":"OG001","value":"6.8","spread":"0.41"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.06"},{"groupId":"OG001","value":"-1.2","spread":"1.30"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.22"},{"groupId":"OG001","value":"-1.8","spread":"1.79"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.63"},{"groupId":"OG001","value":"-2.4","spread":"1.82"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"1.96"},{"groupId":"OG001","value":"-2.8","spread":"2.39"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression: Improvement Scale (CGI-I) Scores","description":"The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse; where higher scores indicated worst outcomes. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.37"},{"groupId":"OG001","value":"4.0","spread":"0.00"}]}]},{"title":"Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"0.52"},{"groupId":"OG001","value":"4.5","spread":"0.84"}]}]},{"title":"Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.81"},{"groupId":"OG001","value":"3.6","spread":"0.89"}]}]},{"title":"Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.81"},{"groupId":"OG001","value":"3.7","spread":"1.37"}]}]},{"title":"Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.81"},{"groupId":"OG001","value":"3.0","spread":"1.10"}]}]},{"title":"Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.30"},{"groupId":"OG001","value":"4.0","spread":"1.41"}]}]},{"title":"Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.52"},{"groupId":"OG001","value":"3.2","spread":"1.92"}]}]},{"title":"Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.53"},{"groupId":"OG001","value":"2.8","spread":"1.10"}]}]},{"title":"Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.21"},{"groupId":"OG001","value":"2.4","spread":"1.14"}]}]},{"title":"Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.58"},{"groupId":"OG001","value":"2.6","spread":"1.95"}]}]},{"title":"Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.89"},{"groupId":"OG001","value":"2.4","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glasgow Coma Scale (GCS) Scores","description":"The Glasgow Coma Scale is divided into three components which are scored separately: ocular response (assessment 1-4 points), motor response (assessment 1-6 points), verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total score that will range between a minimum of 3 points (which corresponds to a participant who does not open his/her eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a participant with open eyes, obeying orders and maintaining a consistent language). It has been considered that the GCS score between 15 and 13 points corresponds to a slight alteration of consciousness, a score of 12-9 points with moderate impairment and 8 points or less with a serious deterioration in level of consciousness.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline (Screening) to infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for 95 hours from Days 1 to 4 followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"1.88"},{"groupId":"OG001","value":"3.5","spread":"1.22"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.26"},{"groupId":"OG001","value":"-0.2","spread":"0.45"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.63"},{"groupId":"OG001","value":"-0.5","spread":"1.22"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.21"},{"groupId":"OG001","value":"1.4","spread":"1.34"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.16"},{"groupId":"OG001","value":"1.3","spread":"2.42"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"3.16"},{"groupId":"OG001","value":"3.0","spread":"3.69"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"3.30"},{"groupId":"OG001","value":"3.3","spread":"3.93"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"3.98"},{"groupId":"OG001","value":"5.0","spread":"4.90"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"4.53"},{"groupId":"OG001","value":"5.0","spread":"4.90"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"4.73"},{"groupId":"OG001","value":"5.4","spread":"5.27"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"4.99"},{"groupId":"OG001","value":"6.4","spread":"4.83"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"5.70"},{"groupId":"OG001","value":"7.4","spread":"4.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Richmond Agitation Sedation Scale (RASS) Score","description":"The RASS was an assessment of agitation and sedation in hospitalized participants, using a 10 point scale (ranged from -5 to +4), where, -5 = Unarousable, -4 = Deep sedation, -3 = Moderate sedation, -2 = Light sedation, -1 = Drowsy, 0 = Alert and calm, +1 = Restless, +2 = Agitated, +3 = Very agitated and +4 = Combative. Lower scores signify higher levels of sedation and higher scores signify heightened agitation. Participant in a calm and alert state would score a 0.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion. Number analyzed is the number of participants with data available for analyses at the given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline (Screening) to Infusion at 0-24, 25-48, 49-72, 73-96, 97-120 hours; Acute follow-up at 121-144, 145-168 hours; Extended follow-up at Days 8, 15, 22 and 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"0.54"},{"groupId":"OG001","value":"-4.8","spread":"0.41"}]}]},{"title":"CFB at Infusion: 0-24 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.25"},{"groupId":"OG001","value":"0.0","spread":"0.00"}]}]},{"title":"CFB at Infusion: 25-48 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.44"},{"groupId":"OG001","value":"0.0","spread":"0.00"}]}]},{"title":"CFB at Infusion: 49-72 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"1.32"},{"groupId":"OG001","value":"0.8","spread":"1.30"}]}]},{"title":"CFB at Infusion: 73-96 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.41"},{"groupId":"OG001","value":"0.7","spread":"1.21"}]}]},{"title":"CFB at Infusion: 97-120 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.59"},{"groupId":"OG001","value":"1.3","spread":"1.75"}]}]},{"title":"CFB at Acute Follow-up: 121-144 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"1.97"},{"groupId":"OG001","value":"1.3","spread":"1.97"}]}]},{"title":"CFB at Acute Follow-up: 145-168 hours","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.24"},{"groupId":"OG001","value":"1.4","spread":"1.67"}]}]},{"title":"CFB at Extended Follow-up: Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.16"},{"groupId":"OG001","value":"2.4","spread":"2.61"}]}]},{"title":"CFB at Extended Follow-up: Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.79"},{"groupId":"OG001","value":"2.2","spread":"1.92"}]}]},{"title":"CFB at Extended Follow-up: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.91"},{"groupId":"OG001","value":"2.8","spread":"2.17"}]}]},{"title":"CFB at Extended Follow-up: Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.22"},{"groupId":"OG001","value":"2.8","spread":"2.17"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Survived","description":"Survival time was defined as duration of survival from screening up to Day 29.","populationDescription":"Efficacy population included all participants who completed the SAGE-547 infusion and who had at least one attempt to wean the third-line agent(s) before the start of the taper of the SAGE-547 infusion.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 29","groups":[{"id":"OG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for next 95 hours from Days 1 to 4 (i.e. up to Hour 96) followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5."},{"id":"OG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of SAGE-547 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of SAGE-547 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to 29 days","description":"Safety Population included all participants who were initiated with an infusion of SAGE-547.","eventGroups":[{"id":"EG000","title":"SAGE-547 Standard Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion of 86 μg/kg/hr for 95 hours from Days 1 to 4 followed by taper infusions of 64.5 μg/kg/hr, 43.0 μg/kg/hr, 21.5 μg/kg/hr at a duration of 8 hours each, on Day 5.","deathsNumAffected":5,"deathsNumAtRisk":19,"seriousNumAffected":14,"seriousNumAtRisk":19,"otherNumAffected":15,"otherNumAtRisk":19},{"id":"EG001","title":"SAGE-547 High Dose","description":"Participants received SAGE-547 IV loading infusion of 286.6 μg/kg/hr for 1 hour on Day 1 followed by maintenance infusion A of 86 μg/kg/hr for 23 hours on Day 1 followed by maintenance infusion B of 156 μg/kg/hr for 72 hours from Days 2 to 4 followed by taper infusions of 125 μg/kg/hr, 94 μg/kg/hr, 62 μg/kg/hr, 31 μg/kg/hr at a duration of 6 hours each, on Day 5.","deathsNumAffected":1,"deathsNumAtRisk":6,"seriousNumAffected":2,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Tracheostomy infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Chemical poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Post procedural haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Wound dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Critical illness polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Haemodynamic instability","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Obstructive shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Brain neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]}],"otherEvents":[{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Enterococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Paraspinal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Bacterial tracheitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Pneumonia pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Urinary tract infection fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Abdominal compartment syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Lip dry","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Swollen tongue","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Blood bicarbonate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"ECG signs of myocardial ischaemia","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Glucose urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Ammonia increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood chloride increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Carbon dioxide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Haematocrit decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Monocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":3,"numAtRisk":6}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Fluid retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hyperammonaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Lactic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Hypothermia","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Miliaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Haemorrhagic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Thrombocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Anaemia postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":2,"numAtRisk":6}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Nodal rhythm","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Increased bronchial secretion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":19},{"groupId":"EG001","numAffected":1,"numAtRisk":6}]},{"term":"Pupils unequal","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":19},{"groupId":"EG001","numAffected":0,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution)."},"pointOfContact":{"title":"Medical Monitor","organization":"Sage Therapeutics","email":"info@sagerx.com","phone":"(617) 299-8380"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D013226","term":"Status Epilepticus"}],"ancestors":[{"id":"D012640","term":"Seizures"},{"id":"D009461","term":"Neurologic Manifestations"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000625635","term":"brexanolone"}]}},"hasResults":true}